Swedish healthcare group Sobi has appointed Torbjorn Hallberg as its new general counsel and establishes a new leadership structure.
Hallberg, who joins from Takeda, where he served for seven years, first as senior director and corporate counsel and then more recently as its vice president, general counsel for emerging markets.
He arrives at Sobi will more than 15 years’ experience covering licensing, mergers and acquisitions at pharma groups such as Ferring and Nycomed.
Meanwhile, Sobi has also established a new leadership structure, consisting of chief executive officer Guido Oelkers, chief financial officer Mats-Olof Wallin, general counsel and head of legal affairs Carin Dahlquist (an acting role), head of EMENA Hege Hellström and head of North America Rami Levin.
Also sitting on the new team are Sobi’s head of specialty care Norbert Oppitz, head of medical and scientific affairs Armin Reininger, head of haemophilia Philip Wood and head of research and development and chief medical officer Milan Zdravkovic.
Source: PMLive
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
